News

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial with the genetically modified ChAd155-RSV vaccine from the company GlaxoSmithKline Biologicals. The purpose of this trial is to provide critical information on the safety, reactogenicity and immunogenicity profile of the ChAd155-RSV vaccine in infants, as well as on the risk of vaccine-induced enhanced RSV disease after vaccination. The public consultation runs from 26 November 2018 to 26 December 2018 inclusive.

Submission of dossiers and documents to the Research and Development Division (human use) of the FAMHP via the CESP is compulsory since 1 October 2018. Today, the FAMHP publishes version 1.2 of the guidance.

The battle against anti-microbial resistance (AMRI) is one of the greatest challenges for our society according to the World Health Organization. Diseases are transferred from humans to animals and vice versa, so actions must be taken for prevention and fighting AMR in both the human and veterinary sector, and even on the level of the environment. This is why the FAMHP, together with all of the authorities involved, are committed to an inter-sector strategy in the battle against AMR, according to the principle of “One World One Health”.

Last updated on 29/06/2017